Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.
The insulin-like growth factor 1 receptor (IGF-1R) may be involved in the development of resistance against conventional cancer treatment. The aim of this study was to assess whether IGF-1R expression of breast tumors changes during neoadjuvant therapy and to study whether these changes were associa...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4334229?pdf=render |
| _version_ | 1831812647274676224 |
|---|---|
| author | Sandra Heskamp Otto C Boerman Janneke D M Molkenboer-Kuenen Carla A Wauters Luc J A Strobbe Caroline M P W Mandigers Peter Bult Wim J G Oyen Winette T A van der Graaf Hanneke W M van Laarhoven |
| author_facet | Sandra Heskamp Otto C Boerman Janneke D M Molkenboer-Kuenen Carla A Wauters Luc J A Strobbe Caroline M P W Mandigers Peter Bult Wim J G Oyen Winette T A van der Graaf Hanneke W M van Laarhoven |
| author_sort | Sandra Heskamp |
| collection | DOAJ |
| description | The insulin-like growth factor 1 receptor (IGF-1R) may be involved in the development of resistance against conventional cancer treatment. The aim of this study was to assess whether IGF-1R expression of breast tumors changes during neoadjuvant therapy and to study whether these changes were associated with survival.Paraffin embedded tumor tissue was collected from pretreatment biopsies and surgical resections of 62 breast cancer patients who were treated with neoadjuvant chemotherapy or endocrine therapy. IGF-1R expression was determined immunohistochemically and compared before and after treatment.High membranous IGF-1R expression at diagnosis correlated significantly with ER positivity, low tumor stage (stage I/II) and longer overall survival (p < 0.05). After neoadjuvant treatment, membranous IGF-1R expression remained the same in 41 (65%) tumors, was upregulated in 11 (18%) tumors and downregulated in 11 (18%) tumors. Changes in membranous IGF-1R expression were associated with overall survival (log-rank test: p = 0.013, multivariate cox-regression: p = 0.086). Mean overall survival time for upregulation, no change, and downregulation in IGF-1R expression was 3.0 ± 0.5 years, 7.3 ± 1.0 years and 15.0 ± 1.8 years, respectively. Changes in other parameters were not significantly associated with survival.Neoadjuvant therapy can induce changes in IGF-1R expression. Upregulation of IGF-1R expression after neoadjuvant treatment is a poor prognostic factor in breast cancer patients, providing a rationale for incorporating anti-IGF-1R drugs in the management of these patients. |
| first_indexed | 2024-12-22T21:40:19Z |
| format | Article |
| id | doaj.art-e7c31453e4b94b88b064c2385dfa4980 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T21:40:19Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e7c31453e4b94b88b064c2385dfa49802022-12-21T18:11:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01102e011774510.1371/journal.pone.0117745Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.Sandra HeskampOtto C BoermanJanneke D M Molkenboer-KuenenCarla A WautersLuc J A StrobbeCaroline M P W MandigersPeter BultWim J G OyenWinette T A van der GraafHanneke W M van LaarhovenThe insulin-like growth factor 1 receptor (IGF-1R) may be involved in the development of resistance against conventional cancer treatment. The aim of this study was to assess whether IGF-1R expression of breast tumors changes during neoadjuvant therapy and to study whether these changes were associated with survival.Paraffin embedded tumor tissue was collected from pretreatment biopsies and surgical resections of 62 breast cancer patients who were treated with neoadjuvant chemotherapy or endocrine therapy. IGF-1R expression was determined immunohistochemically and compared before and after treatment.High membranous IGF-1R expression at diagnosis correlated significantly with ER positivity, low tumor stage (stage I/II) and longer overall survival (p < 0.05). After neoadjuvant treatment, membranous IGF-1R expression remained the same in 41 (65%) tumors, was upregulated in 11 (18%) tumors and downregulated in 11 (18%) tumors. Changes in membranous IGF-1R expression were associated with overall survival (log-rank test: p = 0.013, multivariate cox-regression: p = 0.086). Mean overall survival time for upregulation, no change, and downregulation in IGF-1R expression was 3.0 ± 0.5 years, 7.3 ± 1.0 years and 15.0 ± 1.8 years, respectively. Changes in other parameters were not significantly associated with survival.Neoadjuvant therapy can induce changes in IGF-1R expression. Upregulation of IGF-1R expression after neoadjuvant treatment is a poor prognostic factor in breast cancer patients, providing a rationale for incorporating anti-IGF-1R drugs in the management of these patients.http://europepmc.org/articles/PMC4334229?pdf=render |
| spellingShingle | Sandra Heskamp Otto C Boerman Janneke D M Molkenboer-Kuenen Carla A Wauters Luc J A Strobbe Caroline M P W Mandigers Peter Bult Wim J G Oyen Winette T A van der Graaf Hanneke W M van Laarhoven Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. PLoS ONE |
| title | Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. |
| title_full | Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. |
| title_fullStr | Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. |
| title_full_unstemmed | Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. |
| title_short | Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. |
| title_sort | upregulation of igf 1r expression during neoadjuvant therapy predicts poor outcome in breast cancer patients |
| url | http://europepmc.org/articles/PMC4334229?pdf=render |
| work_keys_str_mv | AT sandraheskamp upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT ottocboerman upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT jannekedmmolkenboerkuenen upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT carlaawauters upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT lucjastrobbe upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT carolinempwmandigers upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT peterbult upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT wimjgoyen upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT winettetavandergraaf upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients AT hannekewmvanlaarhoven upregulationofigf1rexpressionduringneoadjuvanttherapypredictspooroutcomeinbreastcancerpatients |